Volume 12, Issue 4, April 2024, Pages 1067-1070Author links open overlay panelFabien Beaufils MD, PhD a b c, Pauline Esteves PhD a c, Raphael Enaud MD, PhD a b c, Renaud Prevel MD, PhD a b c, Pauline Henrot MD, PhD a b c, Marilyne Campagnac BSc a c, Elise Maurat BSc a c, Marine Michelet MD d e, Frederic Lavrand MD b, Hugues Begueret MD, PhD b, Thomas Trian PhD a c, Michael Fayon MD, PhD a b c, Patrick Berger MD, PhD a b c

P’tit Asthme Study Group∗

Show morePrevious article in issueNext article in issue

Recommended articles

This study has received a research grant from the French Ministry of Health (grant numbers: B101222-30 and 2010-A01134-35) and the “Fondation Bordeaux Université (Fonds FGLMR/AVAD pour les Maladies Chroniques).”

Conflicts of interest: F. Beaufils has received a research grant from AstraZeneca and reports personal fees and nonfinancial support from Novartis, Chiesi, and AstraZeneca. R. Prevel has received support to attend conferences by Pfizer and GSK, and a research grant from CSL Behring. P. Henrot reports a research grant and nonfinancial support from FGLMR/Avad and nonfinancial support from Chiesi and GlaxoSmithKine. V. Siao-Him-Fa reports personal fees from Chiesi, Novartis, and ALK, and nonfinancial support from Novartis, Boehringer Ingelheim, and ALK. M. Michelet reports personal fees and nonfinancial support from Astra Zeneca, GSK, Novartis, and Sanofi. M. Fayon has received a research and educational grant from Novartis and reports personal fees as a speaker from GlaxoSmithKine. In addition, M. Fayon has 1 co-patent (number: FR 19/14751: ie, New in situ pulmonary treatment device in premature babies). P. Berger is the medical coordinator of the French national cohort (ie, COBRA), which received grants from AstraZeneca, GlaxoSmithKine, Roche, Chiesi, Novartis, and Legs Poix Foundation. He reports grants from Novartis and Boehringer Ingelheim; personal fees from Novartis, Chiesi, Boehringer Ingelheim, AstraZeneca, Sanofi, Menarini, and TEVA; and nonfinancial support from Chiesi, Boehringer Ingelheim, AstraZeneca, and Sanofi, outside the submitted work. In addition, P. Berger has 3 patents: (1) (EP number: 15152886.6, ie, New compositions and methods of treating and/or preventing chronic obstructive pulmonary disease), pending; (2) (EP number: 3050574, ie, Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease), delivered; and (3) (EP number: 20173595.8, ie, New compositions and methods of treating COVID-19 disease), pending. The rest of the authors declare that they have no relevant conflicts of interest.

∗

Members of the P’tit Asthme Study Group are listed below the Acknowledgments section.

© 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.

Recommended articlesArticle Metrics